Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study-Reference-Cited by-同舟云学术

Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study

Published:2023-04 Issue: Volume:33 Page:100690
ISSN:2666-6065
Container-title:The Lancet Regional Health - Western Pacific
language:en
Short-container-title:The Lancet Regional Health - Western Pacific

Author:

Quan Jianchao^ORCID,Zhao Zhenping,Wang Limin,Ng Carmen S.^ORCID,Kwok Harley H.Y.^ORCID,Zhang Mei,Zhou Sunyue^ORCID,Ye Jiaxi^ORCID,Ong Xin Jiong^ORCID,Ma Robyn^ORCID,Leung Gabriel M.^ORCID,Eggleston Karen^ORCID,Zhou Maigeng^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine

Reference35 articles.

1. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022

2. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China [in Chinese];Zhonghua Nei Ke Za Zhi,1981

3. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study;Li;BMJ,2020

4. Burden of diabetes, hyperglycaemia in China from to 2016: findings from the 1990 to 2016, global burden of disease study;Liu;Diabetes Metab,2019

5. Interpretation of the diabetes prevention and control action of the Healthy China initiative 2019−2030;Wang;China CDC Wkly,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide;Diabetes, Obesity and Metabolism;2024-05-13

2. Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study;Diabetes, Obesity and Metabolism;2024-03-18

3. Double hits with bioactive nanozyme based on cobalt-doped nanoglass for acute and diabetic wound therapies through anti-inflammatory and pro-angiogenic functions;Bioactive Materials;2024-01

4. Apigenin ameliorates diabetic neuropathy in rats by modulating the TLR4/MyD88 signaling pathway;Asian Pacific Journal of Tropical Biomedicine;2023-11